OpenAlex
PricingAboutJobs
Log inGet started
Author

Yuan Yuan

Institutions: General Hospital of Shenyang Military Region, Xuzhou Central Hospital, Liaoning Cancer Hospital & Institute
Observed institutions: General Hospital of Shenyang Military Region, Xuzhou Central Hospital, Liaoning Cancer Hospital & Institute
ORCID: 0000-0002-4241-8902
Observed ORCID: 0000-0002-4241-8902
OpenAlex ID: A5034436575
Phase 2 Study of the PD-1 Inhibitor Serplulimab plus the Bevacizumab Biosimilar HLX04 in Patients with Previously Treated Advanced Hepatocellular Carcinoma
2022 · Zhenggang Ren, Guoliang Shao, et al. · Liver Cancer · 16
PDF
The correlation between novel antidiabetic agents utilization and hepatocellular carcinoma incidence in type 2 diabetes patients: a network meta-analysis
2025 · Junjie Lin, Tianshu Ren, et al. · European Journal of Clinical Pharmacology · 6
Phase 2 study of serplulimab with the bevacizumab biosimilar HLX04 in the first-line treatment of advanced hepatocellular carcinoma
2025 · Zhenggang Ren, Guoliang Shao, et al. · Cancer Immunology Immunotherapy · 5
PDF
Works count: 4
Citation count: 32
H-index: 4
I10-index: 1
Year
Topic
Type
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms